Statement: There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 53/218 (24.31%)   Febrile Neutropenia 2/218 (0.92%)   Neutropenia 2/218 (0.92%)   Anaemia 1/218 (0.46%)   Thrombocytopenia 1/218 (0.46%)   Pancytopenia 0/218 (0.00%)   Left Ventricular Dysfunction 4/218 (1.83%)   Atrial Fibrillation 0/218 (0.00%)   Angina Unstable 0/218 (0.00%)   Arteriospasm Coronary 1/218 (0.46%)   Cardiac Arrest 1/218 (0.46%) Adverse Events 2:   Total: 58/228 (25.44%)   Febrile Neutropenia 1/228 (0.44%)   Neutropenia 1/228 (0.44%)   Anaemia 0/228 (0.00%)   Thrombocytopenia 1/228 (0.44%)   Pancytopenia 1/228 (0.44%)   Left Ventricular Dysfunction 13/228 (5.70%)   Atrial Fibrillation 2/228 (0.88%)   Angina Unstable 1/228 (0.44%)   Arteriospasm Coronary 0/228 (0.00%)   Cardiac Arrest 0/228 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 21/82 (25.61%)   Neutrophils count decreased 1/82 (1.22%)   Cardiac ischemia/infarction 1/82 (1.22%)   Left ventricular systolic dysfunction 1/82 (1.22%)   Hypertension 1/82 (1.22%)   Supraventricular and nodal arrhythmia 1/82 (1.22%)   Anorexia 1/82 (1.22%)   Gastrointestinal perforation 1/82 (1.22%)   Vomiting 1/82 (1.22%)   Dehydration 1/82 (1.22%)   Diarrhoea 1/82 (1.22%)